Academic Journal
Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation
| العنوان: | Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation |
|---|---|
| المؤلفون: | Nelli S. Lakis, Alexander S. Brodsky, Galina Karashchuk, Amanda J. Audesse, Dongfang Yang, Ashlee Sturtevant, Kara Lombardo, Ian Y. Wong, Ashley E. Webb, Douglas C. Anthony |
| المصدر: | Acta Neuropathologica Communications, Vol 10, Iss 1, Pp 1-15 (2022) |
| بيانات النشر: | BMC, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Neurology. Diseases of the nervous system |
| مصطلحات موضوعية: | Glioblastoma, Cancer stem cells, SOX2, CD133, MGMT, Neurology. Diseases of the nervous system, RC346-429 |
| الوصف: | Abstract A growing body of evidence supports the presence of a population of cells in glioblastoma (GBM) with a stem cell-like phenotype which shares certain biological markers with adult neural stem cells, including expression of SOX2, CD133 (PROM1), and NES (nestin). This study was designed to determine the relationship between the expression of these stem cell markers and the clinical outcome in GBM patients. We quantified the intensity of expression of the proteins CD133 and SOX2 by immunohistochemistry (IHC) in a cohort of 86 patients with IDH-wildtype GBM, and evaluated patient outcomes using Kaplan–Meier and Cox proportional hazards analysis. In our patients, MGMT promoter methylation status and age were predictors of overall survival and progression free survival. The levels of SOX2 and CD133 were not associated with outcome in univariate analysis; however, stratification of tumors based on low or high levels of CD133 or SOX2 expression revealed that MGMT methylation was a predictor of progression-free survival and overall survival only for tumors with high levels of expression of CD133 or SOX2. Tumors with low levels of expression of CD133 or SOX2 did not show any relationship between MGMT methylation and survival. This relationship between MGMT and stem cell markers was confirmed in a second patient cohort, the TCGA dataset. Our results show that stratification of GBM by the level of expression of CD133 and SOX2 improved the prognostic power of MGMT promoter methylation status, identifying a low-expressing group in which the clinical outcome is not associated with MGMT promoter methylation status, and a high-expressing group in which the outcome was strongly associated with MGMT promoter methylation status. These findings support the concept that the presence of a high stem cell phenotype in GBM, as marked by expression of SOX2 or CD133, may be associated with the clinical response to treatment. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2051-5960 92656153 |
| Relation: | https://doaj.org/toc/2051-5960 |
| DOI: | 10.1186/s40478-022-01459-9 |
| URL الوصول: | https://doaj.org/article/d5691a8a61b44c2b926561532afe4f88 |
| رقم الانضمام: | edsdoj.5691a8a61b44c2b926561532afe4f88 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 20515960 92656153 |
|---|---|
| DOI: | 10.1186/s40478-022-01459-9 |